1AKRO Stock Overview

Engages in the development of treatments for patients with serious metabolic diseases in the United States. More details

1AKRO fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Akero Therapeutics, Inc. Competitors

Philogen

BIT:PHIL

€910.5m

Ulisse Biomed

BIT:UBM

€18.4m

Arterra Bioscience

BIT:ARBS

€14.9m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.6b

Price History & Performance

Summary of share price highs, lows and changes for Akero Therapeutics
Historical stock prices
Current Share Price	US$34.99
52 Week High	US$0
52 Week Low	US$0
Beta	-0.13
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-2.91%

Recent updates

Shareholder Returns

	1AKRO	IT Biotechs	IT Market
7D	-3.1%	1.6%	2.9%
1Y	n/a	0.3%	14.1%

Return vs Industry: Insufficient data to determine how 1AKRO performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1AKRO performed against the Italian Market.

Price Volatility

Is 1AKRO's price volatile compared to industry and market?
1AKRO volatility
1AKRO Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.4%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1AKRO's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1AKRO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	69	Andrew Cheng	akerotx.com

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.

Akero Therapeutics, Inc. Fundamentals Summary

How do Akero Therapeutics's earnings and revenue compare to its market cap?
1AKRO fundamental statistics
Market cap	€2.86b
Earnings (TTM)	-€241.66m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-11.5x

P/E Ratio

Is 1AKRO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1AKRO income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$269.44m
Earnings	-US$269.44m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-3.38
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	3.3%

How did 1AKRO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/16 03:21
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akero Therapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason Zemansky	BofA Global Research
Alexandria Hammond	BofA Global Research
Edward Nash	Canaccord Genuity

Akero Therapeutics BIT:1AKRO Stock Report